Pfizer drops 10 mg dose of best-selling Xeljanz as study spotlights cardio safety issue, higher rate of deaths
One of Pfizer’s top up-and-coming revenue producers has run into a serious safety issue during a post-marketing study.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
